Agreement - August 22, 2019
Alligator signs agreement with Biotheus
Alligator Bioscience has announced that a license agreement has been reached with Biotheus, a privately held Chinese company based in Zhuhai, Guangdong, China. Under the license agreement, Alligator has granted Biotheus rights in Greater China (including Republic of China, Hongkong, Taiwan and Macau) to an antibody from ALLIGATOR-GOLD for the creation of up to three […]
Clinical Trials - March 11, 2019
First patient dosed in Alligator trial
The first patient has successfully been dosed in the company’s phase I study of ATOR-1015, its drug candidate in development for tumor-directed immunotherapy. ATOR-1015 is designed with properties that shall enable it to accumulate in the tumor area after an intravenous injection, and selectively exert its effect there, states the company in their press release. […]
Agreement - January 25, 2018
Alligator contracts Theradex Oncology as clinical CRO
Alligator Biosciencehas appointed Theradex Oncology as CRO for their planned phase I study of ATOR-1015 for the treatment of metastatic cancer. The upcoming clinical phase I study with ATOR-1015 is a first-in-human dose escalation study in patients with metastatic cancer. The study will be conducted at five sites in Sweden and Denmark. “Engaging Theradex is a key step […]
Biotech Business - December 7, 2017
Alligator expands its management team
Alligator Bioscience announces the expansion of its management team with the appointment of Charlotte A Russell, MD, PhD, as Chief Medical Officer and Peter Ellmark, PhD, Associate professor, as Vice President Discovery. Dr Russell will be responsible for leading Alligator’s clinical team in progressing the company’s immuno-oncology projects towards proof of concept in cancer patients. […]
Clinical Trials - November 9, 2017
Promising results from Alligator Bioscience
Alligator Bioscience has announced results from a clinical phase I first-in-human study of the drug candidate ADC-1013 (JNJ-64457107), a human, monospecific, agonistic, IgG1 antibody targeting the co-stimulatory receptor CD40. The study results show that ADC-1013 is generally well tolerated and support further clinical development of ADC-1013 as a mono- or combination therapy. The data will […]
Agreement - September 15, 2017
Alligator Bioscience in research agreement
Alligator Bioscience has signed a research collaboration agreement with Professor Ignacio Melero, MD, PhD, Center for Applied Medical Research (CIMA) and Clínica Universidad de Navarra, Spain, to further investigate the biology of 4-1BB (CD137) as a target in cancer immunotherapy. Alligator has two pipeline programs targeting 4-1BB, the fully owned monospecific antibody ATOR-1017, and the bispecific antibody ALG.APV-527, […]
